Copyright
©2010 Baishideng. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2010; 2(2): 109-116
Published online Feb 15, 2010. doi: 10.4251/wjgo.v2.i2.109
Published online Feb 15, 2010. doi: 10.4251/wjgo.v2.i2.109
A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy
Tristan D Yan, Stine Munkholm-Larsen, Department of Cardiothoracic Surgery, University of Sydney, Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown, NSW 2050, Australia
Christopher Qian Cao, Department of Surgery, John Hunter Hospital, Newcastle, NSW 2305, Australia
Author contributions: All of the authors participated in designing the study, drafting, editing and revising the article; All authors approved the manuscript.
Correspondence to: Tristan D Yan, BSc (Med), MBBS, PhD, Department of Cardiothoracic Surgery, University of Sydney, Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown, NSW 2050, Australia. tristan.yan@unsw.edu.au
Telephone: +61-2-95150111 Fax: +61-2-95158184
Received: April 27, 2009
Revised: July 23, 2009
Accepted: July 30, 2009
Published online: February 15, 2010
Revised: July 23, 2009
Accepted: July 30, 2009
Published online: February 15, 2010
Abstract
Perioperative intraperitoneal chemotherapy in combination with cytoreductive surgery has been shown to be of benefit for treating selected patients with peritoneal surface malignancy. It has become a new standard of care in the management of diffuse malignant peritoneal mesothelioma and peritoneal dissemination of appendiceal malignancy. Numerous recent publications on carcinomatosis from colorectal cancer and gastric cancer identify groups of patients that would benefit from this local-regional approach for prevention and treatment of carcinomatosis. This review focuses on pharmacological information regarding intraperitoneal chemotherapeutic agents commonly used in gastrointestinal oncology.
Keywords: Intraperitoneal chemotherapy; Mitomycin C; Doxorubicin; Cisplatin 5-fluorouracil; Paclitaxel; Peritoneal surface